Biopharmaceuticals

Teknova to Report Second Quarter 2021 Financial Results on August 11

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Life sciences, Biology, Articles, Biopharmaceuticals, Bioproduction, Bioprocess, Molecular diagnostics, Reagent

HOLLISTER, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will report its financial results for the second quarter of 2021 on Wednesday, August 11, 2021, following the close of market.

Key Points: 
  • HOLLISTER, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will report its financial results for the second quarter of 2021 on Wednesday, August 11, 2021, following the close of market.
  • ET to discuss the Companys financial results and provide a business update.
  • Participants may access the live webcast on the Investor Relations section of the Teknova website, where it will be archived for 30 days, and at this link: https://edge.media-server.com/mmc/p/avgvftny .
  • Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics.

IMC Supports National Biomanufacturing and Life Sciences Strategy Commitment to Ensuring Best-in-Class Regulation

Retrieved on: 
Thursday, July 29, 2021
Life sciences, Articles, Economic taxonomy, Biotechnology, Biomanufacturing, Biopharmaceuticals, Food industry, Pharmaceutical industry, IMC

Ottawa, Ontario--(Newsfile Corp. - July 29, 2021) - Innovative Medicines Canada (IMC) is the national voice for Canada's innovative pharmaceutical industry.

Key Points: 
  • Ottawa, Ontario--(Newsfile Corp. - July 29, 2021) - Innovative Medicines Canada (IMC) is the national voice for Canada's innovative pharmaceutical industry.
  • Today, Innovation, Science and Economic Development Canada (ISED) and Health Canada launched Canada's Biomanufacturing and Life Sciences Strategy .
  • This five-pillar national strategy signals the federal government's commitment to collaborating with industry and other stakeholders in ensuring a robust life sciences sector to develop and deliver innovative medicines and vaccines.
  • IMC and its members applaud the announcement of a national strategy and remain committed to being a trusted partner in building a strong life sciences sector in Canada.

Bota Bio Raises $100 Million Series B Financing to Advance Sustainable Biomanufacturing

Retrieved on: 
Thursday, July 29, 2021
Life sciences, Articles, Economic taxonomy, Biopharmaceuticals, Biotechnology, Biomanufacturing, Global

SAN FRANCISCO and HANGZHOU, China, July 29, 2021 /PRNewswire/ -- Bota Bio, a global industrial biotechnology company advancing sustainable biomanufacturing, today announced that it has raised more than $100 million in an oversubscribed Series B funding round.

Key Points: 
  • SAN FRANCISCO and HANGZHOU, China, July 29, 2021 /PRNewswire/ -- Bota Bio, a global industrial biotechnology company advancing sustainable biomanufacturing, today announced that it has raised more than $100 million in an oversubscribed Series B funding round.
  • This Series B financing brings Bota Bio's total funding to $145 million to date.
  • Bota Bio is a global industrial biotechnology company focused on programming biological systems for the clean and efficient biomanufacturing of common household and industrial products.
  • Tweet This: Global industrial biotechnology company Bota Bio raises $100M series B funding in a round led by Sequoia Capital China.

The Government of Canada announces biomanufacturing and life sciences strategy

Retrieved on: 
Wednesday, July 28, 2021
Articles, Life sciences, Countries, Biopharmaceuticals, Biotechnology, Biomanufacturing, Food industry, Pharmaceutical industry, Patty Hajdu, Minister of Health, Canada

The Government of Canada has already invested over $1.2billion to rebuild Canada's vaccine, therapeutics and biomanufacturing capacity right here at home.

Key Points: 
  • The Government of Canada has already invested over $1.2billion to rebuild Canada's vaccine, therapeutics and biomanufacturing capacity right here at home.
  • As Canadians begin to look towards a post-pandemic future, the Government of Canada continues to build resiliency in Canada's biomanufacturing and life sciences sector as part of the government's recovery plan.
  • Today, the Honourable Franois-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Patty Hajdu, Minister of Health, launched the Biomanufacturing and Life Sciences Strategy.
  • The Biomanufacturing and Life Sciences Strategy is driven by two objectives: to grow a strong, competitive domestic life sciences sector, with cutting-edge biomanufacturing capabilities, while creating good jobs for Canadians, and to make sure Canada is prepared for pandemics and other health emergencies in the future.

Debut Biotech and DIC Enter into Joint Development to Biomanufacture Natural, Sustainable Colors

Retrieved on: 
Wednesday, July 28, 2021
Natural sciences, Life sciences, Articles, Biopharmaceuticals, Biotechnology, Biomanufacturing, Food industry, Pharmaceutical industry, DIC Corporation, DIC Entertainment, Fine chemical, DIC

SAN DIEGO, July 28, 2021 /PRNewswire-PRWeb/ --Today, Debut Biotech , a next generation biomanufacturing platform harnessing cell-free enzymes announced entry into a joint development with DIC , a fine chemicals company.

Key Points: 
  • SAN DIEGO, July 28, 2021 /PRNewswire-PRWeb/ --Today, Debut Biotech , a next generation biomanufacturing platform harnessing cell-free enzymes announced entry into a joint development with DIC , a fine chemicals company.
  • The multi-million dollar deal, spanning several years, will enable Debut Biotech and DIC to leverage advanced biomanufacturing approaches to produce natural color ingredients to be used across DIC's and Debut's portfolio of products.
  • Traditionally, colors used in consumer products have been derived from plants, animals or synthetically produced from petrochemicals.
  • DIC is also the core of the DIC Group, a multinational organization with operations in more than 60 countries and territories worldwide.

Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458

Retrieved on: 
Wednesday, July 21, 2021
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Drugs, Pharmaceutical companies, Health care, Biopharmaceuticals, Ligand Pharmaceuticals, Asparaginase, Erwinia, Jazz Pharmaceuticals, the Pelican Expression Technology™, Ligand Pharmaceuticals, THE PELICAN EXPRESSION TECHNOLOGY™, LIGAND PHARMACEUTICALS

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has launched Rylaze(asparaginase erwinia chrysanthemi (recombinant)-rywn), also known as JZP458.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has launched Rylaze(asparaginase erwinia chrysanthemi (recombinant)-rywn), also known as JZP458.
  • This partnership with Jazz Pharmaceuticals is one of the core scientific programs that catalyzed our acquisition of Pfenex last year.
  • The Rylaze commercial launch really showcases our highly productive partnership with Jazz and the exceptional ability of our Pelican Expression Technology to enable life-saving therapeutics, said John Higgins, CEO of Ligand.
  • Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Alloy Therapeutics and Echo Investment Capital Create Wheeler Bio to Accelerate the Development of New Antibody Therapeutics

Retrieved on: 
Wednesday, July 21, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Life sciences, Articles, Biopharmaceuticals, Economic taxonomy, Biomanufacturing, Biotechnology, Food industry, Pharmaceutical industry, Biotechnology, Pharmaceutical, Health, Clinical trials, Life sciences, Articles, Biopharmaceuticals, Economic taxonomy, Biomanufacturing, Biotechnology, Food industry, Pharmaceutical industry

Alloy Therapeutics and Echo Investment Capital today announced the formation of Wheeler Bio, a new biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact.

Key Points: 
  • Alloy Therapeutics and Echo Investment Capital today announced the formation of Wheeler Bio, a new biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact.
  • With an initial focus on antibody therapeutics, Wheelers biomanufacturing programs will seamlessly integrate with Alloy Therapeutics preclinical antibody platforms and discovery capabilities.
  • Wheeler Bio is headquartered in Oklahoma City with pilot labs located inside Alloy Therapeutics Boston, MA Facility.
  • Echo Investment Capital is a multi-disciplinary investment firm with experience managing more than $1.2 billion in capital across industries.

Quartic.ai advances continuous biomanufacturing; open sources technology to foster innovation

Retrieved on: 
Tuesday, July 20, 2021
Life sciences, Articles, Economic taxonomy, Biotechnology, Biopharmaceuticals, Biomanufacturing, Food industry, Pharmaceutical industry, Batch process, Pharma, Quartic

The digital twin, which the company has open-sourced, is one of several Quartic initiatives aimed at accelerating the pharmaceutical industry's transition from batch processing to continuous manufacturing of biologics.

Key Points: 
  • The digital twin, which the company has open-sourced, is one of several Quartic initiatives aimed at accelerating the pharmaceutical industry's transition from batch processing to continuous manufacturing of biologics.
  • "Today, more than 90% of biomanufacturing uses batch processing which is costly, slow, and asset intensive," said Rajiv Anand, CEO and founder of Quartic.
  • "AI promises to be a boon to continuous manufacturing and more immediately to process intensification in biomanufacturing.
  • The Quartic Platform was recognized with the 2019 Pharma Innovation Award for Pharma 4.0.

Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors

Retrieved on: 
Wednesday, July 14, 2021
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Physical sciences, Chemistry, Natural sciences, Coordination chemistry, Biopharmaceuticals, Ligand Pharmaceuticals, Ligand

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (Ligand or the Company) announces the appointment of Jennifer Cochran, Ph.D. to the Company's Board of Directors.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (Ligand or the Company) announces the appointment of Jennifer Cochran, Ph.D. to the Company's Board of Directors.
  • We were introduced to Jennifer a year ago during Ligands acquisition of xCella, where she was co-founder and board member.
  • We welcome Jennifer to Ligands Board of Directors and look forward to her contributions.
  • Dr. Cochran has been with Stanford since 2005, with a leave of absence from 2015 to 2017 to focus on entrepreneurial pursuits.

Shorla Pharma Expands into the U.S. with the Opening of a Cambridge, MA Office

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Life sciences, Industry economics), Pharmaceutical companies, Biopharmaceuticals, Biotechnology, Pharmaceutical industry, Specialty drugs in the United States, Sun Pharma

Shorla Pharma Limited (Shorla), a specialty pharmaceutical company, has announced its arrival in the United States locating a base in Boston's innovative Cambridge biotech cluster.

Key Points: 
  • Shorla Pharma Limited (Shorla), a specialty pharmaceutical company, has announced its arrival in the United States locating a base in Boston's innovative Cambridge biotech cluster.
  • Founded in Ireland, Shorla specializes in developing innovative oncology drugs, with a focus on orphan and pediatric cancers, and is rapidly building its U.S. team, headquartered in Cambridge, MA.
  • The company has an advanced pipeline of oncology products to treat a number of unmet patient needs.
  • "It's an honor to bring Shorla's life-changing treatments to patients in the U.S.," said Sharon Cunningham, CEO and Co-founder of Shorla Pharma.